[1] Shah AT,Wu E,Wein RO. Oral squamous cell carcinoma in post-transplant patients[J]. Am J Otolaryngol,2013,34(2):176-179. [2] Box C,Zimmermann M,Eccles S. Molecular markers of response and resistance to EGFR inhibitors in head and neck cancers[J].Front Biosci,2013,1(18):520-542. [3] Orr B,Compton DA. A double-edged sword:how oncogenes and tumor suppressor genes can contribute to chromosomal instability[J]. Front Oncol,2013,27(3):164. [4] Antonicelli A,Cafarotti S,Indini A,et al. EGFR-targeted therapy for non-small cell lung cancer:focus on EGFR oncogenic mutation[J]. Int J Med Sci,2013,10(3):320-330. [5] Masui H, Kawamoto T, Sato J D, et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monclonal antibodies [J]. Cancer Res, 1984, 44(3):1002-1007. [6] da Cunha Santos G,Shepherd FA,Tsao MS.EGFR mutations and lung cancer[J]. Annu Rev Pathol,2011,6:49-69. [7] Gilmour AM,Abdulkhalek S,Cheng TS,et al. A novel epidermal growth factor receptor-signaling platform and its targeted translation in pancreatic cancer[J]. Cell Signal,2013,25(12):2587-2603. [8] de Mello RA,Marques AM,Araújo A. Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies[J]. World J Gastroenterol,2013,19(38):6315-6318. [9] Ovcaricek T,Cufer T,Kern I,et al. Efficacy of tyrosine kinase inhibitors in routine clinical practice: Epidermal growth factor mutations and their implications[J]. J Cancer Res Ther,2013,9(2):261-266. [10] 高扬,周延民,张颖奇,等. STAT3、EGF和EGFR在口腔鳞癌中的表达及其意义[J]. 口腔医学研究,2009,25(3):258-261. [11] Bernardes VF,Gleber-Netto FO,Sousa SF,et al. Clinical significance of EGFR,Her-2 and EGF in oral squamous cell carcinoma:a case control study[J]. J Exp Clin Cancer Res,2010,29:40. |